Author + information
- Received December 13, 2012
- Revision received April 11, 2013
- Accepted April 16, 2013
- Published online July 9, 2013.
- Reza Aghamohammadzadeh, MBChB (Hon)∗,†∗ (, )
- Adam S. Greenstein, MBChB, PhD∗,†,
- Rahul Yadav, MBBS∗,†,
- Maria Jeziorska, MD, PhD∗,
- Salam Hama, MBChB, MSc∗,†,
- Fardad Soltani, BSc†,
- Phil W. Pemberton, MSc†,‡,
- Basil Ammori, MD§,
- Rayaz A. Malik, MBChB, PhD∗,†,
- Handrean Soran, MD∗,† and
- Anthony M. Heagerty, MD, FMedSci∗,†
- ∗Cardiovascular Research Group, University of Manchester, Manchester, United Kingdom
- †Manchester Wellcome Trust Clinical Research Facility, Manchester, United Kingdom
- ‡Department of Clinical Biochemistry, Manchester Royal Infirmary, Manchester, United Kingdom
- §Salford Royal NHS Foundation Trust, Manchester, United Kingdom
- ↵∗Reprint requests and correspondence:
Dr. Reza Aghamohammadzadeh, Cardiovascular Research Group, Core Technology Facility (3rd floor), 46 Grafton Street, Manchester M13 9NT, United Kingdom.
Objectives The aim of this study was to investigate the effects of bariatric surgery on small artery function and the mechanisms underlying this.
Background In lean healthy humans, perivascular adipose tissue (PVAT) exerts an anticontractile effect on adjacent small arteries, but this is lost in obesity-associated conditions such as the metabolic syndrome and type II diabetes where there is evidence of adipocyte inflammation and increased oxidative stress.
Methods Segments of small subcutaneous artery and perivascular fat were harvested from severely obese individuals before (n = 20) and 6 months after bariatric surgery (n = 15). Small artery contractile function was examined in vitro with wire myography, and perivascular adipose tissue (PVAT) morphology was assessed with immunohistochemistry.
Results The anticontractile activity of PVAT was lost in obese patients before surgery when compared with healthy volunteers and was restored 6 months after bariatric surgery. In vitro protocols with superoxide dismutase and catalase rescued PVAT anticontractile function in tissue from obese individuals before surgery. The improvement in anticontractile function after surgery was accompanied by improvements in insulin sensitivity, serum glycemic indexes, inflammatory cytokines, adipokine profile, and systolic blood pressure together with increased PVAT adiponectin and nitric oxide bioavailability and reduced macrophage infiltration and inflammation. These changes were observed despite the patients remaining severely obese.
Conclusions Bariatric surgery and its attendant improvements in weight, blood pressure, inflammation, and metabolism collectively reverse the obesity-induced alteration to PVAT anticontractile function. This reversal is attributable to reductions in local adipose inflammation and oxidative stress with improved adiponectin and nitric oxide bioavailability.
Obesity has become a global public heath challenge affecting almost one-half billion adults (1) and an estimated 40 million children (2). Large artery disease is very common in obese patients and manifests clinically as myocardial infarction, stroke, and hypertension (3). Small artery disease is also common in obesity and contributes to the development of hypertension and microvascular disease due to changes in peripheral resistance and local autoregulation (4). Historically, the small artery dysfunction in obesity has been attributed to damage to the endothelium (5), most notably to generation and release of nitric oxide (NO) (6). More recently, however, appreciation has grown for an additional mechanism by which vascular damage occurs in obesity; the function of fat surrounding arteries, or perivascular adipose tissue (PVAT). The PVAT surrounds the majority of blood vessels in the body and, in addition to adipocytes, contains inflammatory cells, stem cells, and microvasculature. In health, PVAT modulates the contractile tone of adjacent small arteries by secreting vasodilatory molecules. These adipose-derived vasodilators act independently of the endothelium and include adiponectin (7), NO (7), hydrogen sulfide (8), and palmitic acid methyl ester (9). In 2009, we performed the first human small artery study of PVAT and showed that subcutaneous gluteal PVAT from lean healthy individuals reduced adrenergic constriction in adjacent arteries, an “anticontractile” effect. However, in patients with metabolic syndrome the vasodilatory effect of the PVAT was entirely lost, due to dual processes of adipose tissue hypoxia and inflammation, both of which are established sequelae of obesity in fat depots (7). More recently, we have seen that macrophage activation in adipose tissue contributes to the attenuation in PVAT anticontractile effect (10).
Bariatric surgery has been performed for nearly 60 years and is established as the most effective clinical intervention to achieve both significant and sustained weight-loss in severely obese individuals. There are 3 types of bariatric surgical procedures: restrictive, malabsorptive, and combined operations (11). Gastric bypass surgery is a combination of restriction and malabsorption and has been shown to achieve a significantly higher degree of weight loss than restrictive bariatric surgery (12).
Bariatric surgery also dramatically improves cardiovascular risk profiles in obese patients and reduces overall mortality (13,14). The mechanisms that underlie these cardiovascular improvements remain unclear, however. In the present study we investigated the effects of bariatric surgery achieved by the gastric bypass method on the vasodilatory properties of PVAT. We report amelioration of inflammation in PVAT with complete restoration of anticontractile activity as a consequence of improved adiponectin and NO bioavailability, despite persisting obesity.
Patients with severe obesity (body mass index [BMI] >35 kg/m2) who were awaiting gastric bypass surgery (n = 15) and lean healthy volunteers (n = 7) were recruited after full informed written consent in accord with local research ethics committee approval. All participants provided a fasting venous blood sample for the measurement of inflammatory markers and adipokines.
The study participants also provided gluteal subcutaneous fat samples (1.5 × 1.5 × 1.5 cm) by undergoing a surgical biopsy under local anesthesia (7). The sample was immediately processed in 3 sections. One part was stored for immunohistology, the second was snap-frozen for estimation of NO levels, and the remainder was used to harvest small subcutaneous arteries with micro-dissection.
Blood pressure was recorded as a mean of 3 recordings measured with a semi-automated machine (OMRON 705CP, White Medical, Clifton-Upon-Dunsmore, United Kingdom), whereas the participants were seated at rest for 15 min.
Further measurements including BMI and waist circumference were also recorded.
The obese patients were invited to return for a follow-up assessment, including a biopsy, 6 months after bariatric surgery.
High-sensitivity C-reactive protein (hsCRP) was measured in serum by an in-house, antibody sandwich enzyme-linked immunoadsorbent assay technique with anti-human CRP antibodies, calibrators, and controls from Abcam (Cambridge, United Kingdom). Interleukin-6, tumor necrosis factor (TNF)-α, adiponectin, leptin, and resistin were measured in serum, and E-selectin was measured in plasma, all with DuoSet ELISA development kits from R&D Systems (Abingdon, United Kingdom).
One section of the gluteal fat biopsy was placed in chilled physiological saline solution (composition in mmol/l: sodium chloride 118, potassium chloride 3.4, magnesium sulphate 1.2, calcium chloride 1, sodium bicarbonate 25, glucose 11, potassium orthophosphate 1.2) and oxygenated. The dissection dish was placed on ice during microdissection to preserve the integrity of the tissue, whereas arterial segments 250 to 350 μm in diameter were harvested, 1 segment with PVAT intact, and the adjacent segment devoid of PVAT. Both segments came from the same artery.
Endothelium denuded vessels were mounted on 40-μm wires and studied with wire myography (Danish MyoTech, Aarhus, Denmark).
The mounted vessel segments were oxygenated and maintained at a temperature of 37°C before vessel diameter and wall tension was normalized as previously described (7,15). Vessels were challenged with a 60-mmol/l high-potassium physiological saline solution to establish viability and baseline constriction.
Each vessel segment was stimulated with cumulative doses of norepinephrine (Sigma-Aldrich, Dorset, United Kingdom) at the following doses: 10−9; 10−8; 3 × 10−8; 10−7; 3 × 10−7; 5 × 10−7; 10−6; 2 × 10−6; 3 × 10−6; 5 × 10−6; 10−5; 2 × 10−5; and 3 × 10−5 mol/l. Contractile responses to norepinephrine are presented as a percentage of high-potassium physiological saline solution constriction, consistent with published data (7,16–18).
Pharmacological protocols were applied to study the effect of PVAT on adjacent small arteries. In each case 2 segments of the same artery were prepared with and without PVAT attached as previously described (7).
The role of oxidative stress was evaluated by incubation of samples from pre-operative patients with superoxide dismutase and catalase (superoxide dismutase, Sigma-Aldrich, 100-μ/ml incubation period 45 min; and catalase, Sigma-Aldrich, 100-μ/ml incubation period 45 min; n = 4).
Further protocols assessed the contribution of NO and adiponectin to PVAT function in samples taken from patients after weight loss. Arteries with PVAT were incubated with blocking peptide for adiponectin receptor 1 (AdipoR1) (5 μg/ml, 1.6 × 10−4 mol/l, Enzo Life Sciences; 45 min; n = 7) and N5-[imino(methylamino)methyl]-L-ornithine, citrate (5 × 10−5 mol/l, Sigma; 45 min; n = 4).
Five paired pre-operative and post-operative frozen PVAT samples were homogenized by suspending the tissue in 400 μl of lysis buffer (50 mmol/l Tris base, 150 mmol/l sodium chloride, 2 mmol/l ethylenediaminetetraacetic acid, 2 mmol/l ethyleneglycoltetraacetic acid, 40 mmol/l β-glycerophosphate, 50 mmol/l sodium fluoride, 10 mmol/l sodium pyrophosphate, 10% glycerol, 1% Triton X-100 [pH 7.4]) and protease inhibitor (Complete Mini EDTA-Free; Roche Diagnostics, Basel, Switzerland) on ice and using a Dounce (glass/glass) tissue grinder set (Sigma-Aldrich). Upon complete homogenization, the solution was incubated at 4°C for 10 min, then centrifuged for 10 min at 16,000 g. The resulting supernatant was then removed for application of the assay.
Total nitrate/nitrite concentration was measured with a NO colorimetric assay kit according to the instructions of the manufacturer (Abcam).
Macrophage Markers and TNF-α
Immediately after dissection, tissue from each gluteal biopsy consisting of skin and subcutaneous fat was placed in 4% paraformaldehyde in phosphate buffered saline for 24 h and subsequently processed to paraffin wax blocks. Consecutive 5-μm sections were de-waxed, rehydrated, and immunostained for 2 macrophage markers—CD68 [KP1] (Dako, Glostrup, Denmark; dilution 1:100), and CD68 [PGM1] (Biocare Medical, Concord, California; dilution 1:100)—and the pro-inflammatory cytokine TNF-α (Abcam; dilution 1: 100). Antigen retrieval was performed, followed by blocking of endogenous peroxidase and nonspecific protein binding with Dako blocking solutions. Tissue sections were incubated with primary antibodies for 18 h, followed by anti-rabbit/anti-mouse EnVision-HRP (Dako) and finally by Vector SG chromogen kit (Vector Laboratories, Burlingame, California), used to disclose the presence of the macrophages and TNF-α. Color images were captured with a Go-3 QImaging camera (QImaging Corporation, Vancouver, Canada) mounted on a Leitz Diaplan microscope (Leica, Wetzlar, Germany). Cells stained with macrophage markers present in adipose tissue were counted, and the results were expressed as cells/mm2. For assessment of TNF-α, quantitative analysis of immunostaining was obtained, converting color images to greyscale and with a macro subroutine in an ImagePro version 6.2 image analysis program (MediaCybernetics United Kingdom, Marlow, United Kingdom). The extent of staining was expressed as a percentage of the entire area photographed. Adipocyte size was quantified on microphotographs obtained on Zeiss Axio Imager M2 microscope equipped with AxioCam camera and AxioVision Rel. 4.8 program by free-hand tracing the margins of 100 consecutive cells (on average)/case to avoid selection bias (total: 3,000 cells).
Immunohistochemistry for AdipoR1
Five μm deparaffinized formalin-fixed tissue sections were microwaved in citrate buffer pH 6.0, treated with 0.3% hydrogen peroxide, blocked with Protein Block (Dako), and incubated with 1 of the anti-AdipoR1 antibodies, goat polyclonal to AdipoR1 (Abcam), or a rabbit monoclonal to AdipoR1 (Epitomics, Burlingame, California), followed by anti-rabbit/anti-mouse EnVision-HRP (Dako) and Vector SG chromogen kit (Vector Laboratories). The results of immunostaining were compared, and the monoclonal rabbit antibody was selected for further use. Slides were examined and images captured on a Zeiss Axio Imager M2 microscope.
The statistical presentation includes paired and unpaired tests. In the case of ordinal tests, medians and quartiles are used, and for parametric tests mean ± SD is used. Cumulative concentration-response curves were constructed with data obtained by wire myography and analyzed with a 2-way analysis of variance and a Bonferroni post hoc test for each dose. A p value of <0.05 was considered statistically significant. Analyses were performed with the GraphPad Prism 5 software (GraphPad, La Jolla, California).
Study design and participants
Six months after surgery and weight loss, the patients had a significantly lower waist circumference (n = 15; p < 0.0001), BMI (p < 0.0001), and systolic blood pressure (p = 0.0025) (Table 1).
Post-operatively, there was a significant reduction in insulin (p = 0.0042), fasting glucose (p = 0.0312), and hemoglobin A1c (p < 0.0071) and an improvement in pancreatic beta-cell function (homeostatic model assessment of beta-cell function; p < 0.01) and insulin resistance (homeostasis model assessment of insulin resistance; p = 0.0023). After surgery serum levels of adiponectin increased significantly (p = 0.0197), and leptin decreased (p = 0.0014), but resistin levels did not change significantly (p = 0.0796).
Weight-loss surgery restores PVAT anticontractile function
In severely obese patients before surgery and weight-loss, PVAT did not significantly alter the norepinephrine-induced contractility of the small arteries in comparison with skeletonized segments of the same vessels (n = 15, p = 0.96) (Fig. 1A).
In samples taken from patients 6 months after surgery and weight loss, PVAT had a significant anticontractile effect on vessels when compared with vessels without PVAT (n = 15, p < 0.01) (Fig. 1B). The vessels with intact PVAT after surgery had a very similar response to cumulative doses of norepinephrine as the PVAT-intact vessels harvested from healthy lean volunteers (p = 0.52, n = 7) (Fig. 1B). The maximal degree of constriction is lower in PVAT-intact vessels in healthy and post-surgery samples as compared with skeletonized vessels, but the degree of constriction of skeletonized vessels to norepinephrine is similar in segments from pre- and post-surgery (Online Fig. 1).
Anticontractile property of PVAT after weight loss is abolished by adiponectin blockade
Samples taken from patients 6 months after surgery were incubated with blocking peptide for AdipoR1. This had no effect on segments without PVAT, but in vessels with PVAT there was a significant increase in vessel contractility (p < 0.0001, n = 7) (Fig. 2A).
Free radical scavengers can rescue PVAT anticontractile function in obesity
In patients with severe obesity, the presence of perivascular adipose tissue had no effect on vessel contractility in comparison with vessel segments devoid of PVAT. Incubation of the vessels with the free radical scavengers superoxide dismutase and catalase resulted in a shift in the curve to resemble that of vessels with intact PVAT taken from healthy individuals (p < 0.001, n = 7) (Fig. 2B).
Increased NO bioavailability after surgery
There was a significant increase in NO in PVAT of severely obese patients 6 months after surgery (1.016 vs. 1.196 nmol/μl, p = 0.029, n = 5).
In post-surgery samples, de-endothelialized vessel segments were incubated with N5-[imino(methylamino)methyl]-L-ornithine, citrate. The incubation had no effect on vessels without PVAT, but in vessels with PVAT, there was a significant increase in contractility to cumulative doses of norepinephrine (p < 0.001, n = 4) (Fig. 2C).
Reduced PVAT inflammation, adipocyte size, and AdipoR1 after bariatric surgery
There was a significant reduction in the CD68 [KP1] staining macrophage numbers after surgery (7.3 ± 1.1 vs. 4.1 ± 0.7, p = 0.0067, n =14) (Figs. 4C and 4D), but the change in CD68 [PGM1] staining was not statistically changed. There was a significant reduction in the percentage of adipose tissue area staining for TNF-α (1.41 ± 0.34 vs. 0.68 ± 0.09, p < 0.05) (Figs. 4A to 4C) after surgery.
The average adipocyte area was 7,672 ± 369.6 μm2 pre-surgery and 3,955 ± 207.5 μm2 (p < 0.0001) post-surgery (Fig. 4D). The change in average adipocyte area correlated with the change in BMI after surgery (R2 = 0.356, p = 0.0243, n = 14) (Online Fig. 2).
There was a significant reduction in circulating markers of inflammation including hsCRP (p < 0.001), interleukin-6 (p = 0.013), monocyte chemoattractant protein-1 (283.1 vs. 258.3 pg/ml; p = 0.013), and the adhesion molecule E-selectin (12.7 vs. 7.47 ng/ml; p < 0.001). However, there was no significant change in circulating TNF-α levels (p = 0.519) (Table 1).
The present study investigated the effect of bariatric surgery on the vasodilatory properties of PVAT. We designed the study after our earlier observation that, in severely obese patients, although there is an accumulation of adipose tissue, there is also a paradoxical inhibition of the beneficial PVAT vasodilation (7). There are now 3 main findings presented here. First, bariatric surgery reverses the obesity-induced damage to PVAT anticontractile function. Second, the functional recovery of the PVAT is independent of the endothelium. Third, bariatric surgery restores the function of PVAT by reducing adipose inflammation and increasing local adiponectin and NO bioavailability (Figure 5). The observations advance our understanding of the mechanisms by which obesity disrupts the vasodilating function of adipose tissue and how this pathology might be reversed by clinical intervention.
The cardiovascular complications of obesity are undoubtedly among the most pressing issues facing clinicians today (19). To date, the most common recommended intervention has been the encouragement of dietary modification. Effective and sustained dieting does lead, without doubt, to significant weight loss, but unfortunately the weight loss is not sustained (20). Furthermore, the impact of dietary modification on cardiovascular outcomes is unclear (13,21). For patients with severe obesity, the most effective method of achieving significant and sustained weight reduction is by weight-reducing surgery (14). In addition, the weight loss after surgery also significantly correlates with improvements to blood pressure (22,23), left ventricular mass (24), exercise capacity (25), and glucose metabolism (26). Changes to weight in patients are associated with profound modulation of the cytokine and inflammatory profiles of adipose tissue. In this regard, it is now established that, in obese patients, adipose tissue undergoes dual processes of hypoxia and inflammation, leading to a reduction in the secretion of adipocytokines such as adiponectin. The hypoxia is thought to be due to adipocyte hypertrophy (27) twinned with reductions to capillary density and angiogenic capacity (28). This results in up-regulation of hypoxia inducible factor-1 and inflammatory differentiation of macrophages, which subsequently secrete TNF-α (29–31). Differentiated macrophages in obesity also release superoxide anions, which further contribute to local vascular dysfunction by diminishing availability of NO (32).
The functional damage we observe in PVAT and its recovery after bariatric surgery are entirely consistent with this hypoxia/inflammation in fat hypothesis. Thus, in our previous studies we observed adipocyte hypertrophy and increased TNF staining in adipose tissue associated with loss of PVAT vasodilatory function. We now show that, after bariatric surgery, there is restoration of PVAT vasodilatory capacity to a degree that is similar to that observed in healthy non-obese participants. It is interesting to note that this functional restoration of the PVAT occurs even though the patients are still severely obese. The improvement in PVAT function after surgery is associated with smaller adipocytes (in the context of a dramatic weight loss), a reduction in PVAT TNF, and increased local adipose tissue NO bioavailability. Our findings are consistent with other studies that have shown significant reductions in macrophage numbers as well as monocyte chemoattractant protein-1 and hypoxia inducible factor-1α in the stromal vascular fraction of white adipose tissue after bariatric surgery (33). Also, importantly, we show that the functional vasodilatory improvement in the subcutaneous fat is due to restitution of PVAT-derived adiponectin and NO bioavailability.
The functional improvement of PVAT after bariatric surgery was independent of the vascular endothelium, because all arteries in this study were denuded of endothelium. Also notably, there were no differences in constriction of arteries devoid of fat to norepinephrine before and after surgery. Taken together, these observations indicate that the improvement in adipose-vascular coupling after surgery was due to improvements in the vasodilating capacity of the PVAT rather than changes to isolated arterial contractility or endothelial function.
There are a number of limitations to this study that need to be considered in parallel with the findings. We did not monitor the level of exercise performed by the participants at baseline or after surgery, with respect to our patient selection. At 6 months after surgery, the patients had lost a significant amount of weight and were presumably more mobile. As such, we acknowledge that the improvement in PVAT function might be as a consequence of increased levels of mobility. Second, it would have been preferential to recruit participants who were losing weight as part of a calorie-controlled diet to compare changes to PVAT function due to this intervention. This was not possible within the limitations of our faculty, but we hope to perform this study in the future. Similarly, a drawback of this study is that we were not able to perform a 6-month follow-up biopsy on severely obese patients who received no intervention. However, we assume that there would have been no change in PVAT function over this time. We have studied subcutaneous small arteries under the assumption that all small arteries and the surrounding PVAT share similar properties. A separate consideration is that we have detected changes only to subcutaneous gluteal PVAT after surgery. We did not study the function of PVAT from other anatomical sites (i.e., mesenteric or skeletal). As such, we acknowledge that changes to subcutaneous vascular function might not be reflected in other vascular territories, but previous studies have shown similar remodeling profiles of human cerebral and mesenteric arteries to those seen in arteries taken from gluteal subcutaneous biopsies. Finally, it should be noted that norepinephrine was the only contractile agent used. We acknowledge that it would have been preferable to study a variety of vasoconstrictors. However, it should be noted that studies from other groups have shown that PVAT antagonizes contraction to U46619(34), angiotensin II (35,36), phenylephrine (35,37), and serotonin (35,36).
Despite these limitations, however, we believe that we present convincing evidence that PVAT-induced vasodilation of small arteries can be fully restored after bariatric surgery. Furthermore, this restoration of function is due to a reduction in inflammation within the adipose tissue, which leads to increased adiponectin secretion. The data offer an insight into 1 mechanism by which bariatric surgery improves vascular function. We anticipate that further work will harness this observation to improve therapeutic options for the severely obese patient.
The authors thank all the study participants who took part in this study for their time and for providing the invaluable gluteal fat samples as a gift without any remuneration. The authors would also like to thank Aisha Meskiri, Simon Forman, and Louisa Nelson for their help with the sample preparation for immunohistochemical analysis of the tissue and Mahmoud Abudaka for assisting with patient recruitment.
This study was funded by 2 Clinical Research Fellowships awarded to Dr. Aghamohammadzadeh (British Heart Foundation [FS/10/42/ 28372] and NIHR Manchester Biomedical Research Centre); and the support of Wellcome Trust Clinical Research Facility (Manchester, United Kingdom). Dr. Greenstein was funded by the British Heart Foundation (FS11/68/28821). Drs. Greenstein and Heagerty were funded by the British Heart Foundation (FS12/81/29882). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Abbreviations and Acronyms
- adiponectin receptor 1
- body mass index
- high-sensitivity C-reactive protein
- nitric oxide
- perivascular adipose tissue
- tumor necrosis factor
- Received December 13, 2012.
- Revision received April 11, 2013.
- Accepted April 16, 2013.
- 2013 American College of Cardiology Foundation
- ↵WHO. Obesity and Overweight (Factsheet no 311). Available at: http://www.who.int/mediacentre/factsheets/fs311/en/index.html. Accessed August 11, 2009.
- ↵WHO. Population-Based Prevention Strategies for Childhood Obesity. Report of the World Health Organization Forum and Technical Meeting 2009. Available at: http://www.who.int/dietphysicalactivity/childhood/child-obesity-eng.pdf. Accessed June 2013.
- Poirier P.,
- Giles T.D.,
- Bray G.A.,
- et al.
- Jonk A.M.,
- Houben A.J.,
- de Jongh R.T.,
- Serne E.H.,
- Schaper N.C.,
- Stehouwer C.D.
- Greenstein A.S.,
- Khavandi K.,
- Withers S.B.,
- et al.
- Lee Y.C.,
- Chang H.H.,
- Chiang C.L.,
- et al.
- Withers B.S.,
- Agabiti-Rosei C.,
- Livingstone D.M.,
- et al.
- Poirier P.,
- Cornier M.A.,
- Mazzone T.,
- et al.
- ↵Butner KL, Nickols-Richardson SM, Clark SF, Ramp WK, Herbert WG. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg 20:559–68.
- Mulvany M.J.,
- Halpern W.
- Dubrovska G.,
- Verlohren S.,
- Luft F.C.,
- Gollasch M.
- Hofso D.,
- Nordstrand N.,
- Johnson L.K.,
- et al.
- Ballantyne G.H.,
- Wasielewski A.,
- Saunders J.K.
- Pasarica M.,
- Sereda O.R.,
- Redman L.M.,
- et al.
- Halberg N.,
- Khan T.,
- Trujillo M.E.,
- et al.
- Yokota T.,
- Oritani K.,
- Takahashi I.,
- et al.
- Cancello R.,
- Henegar C.,
- Viguerie N.,
- et al.
- Löhn M.,
- Dubrovska G.,
- Lauterbach B.,
- Luft F.C.,
- Gollasch M.,
- Sharma A.M.